To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Takeaways PacBio reported Q4 revenues of $44.6M, up 13.8%, beating estimates.PACB's adjusted gross margin expanded 900 bps to 41%, operating loss narrowed.PACB guides 2026 revenue to $165-$180M, up 3-12% year over year.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, delivered an adjusted loss per share of 12 cents in fourth-quarter 2025, narrower than the year-ago adjusted loss of 20 cents per share. The adjusted loss per share topped the Zacks Consensus Estimate by 36.8%.The ...

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +36.84%. A quarter ago, it was expected that this maker of genetic analysis technology would post a loss of $0.16 per share when it actually produced a loss of $0.12, delivering a surprise of +25%.Over t ...

Pacific Biosciences of California (NasdaqGS:PACB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsChristian Henry - CEODan Brennan - Managing DirectorJim Gibson - CFOKelly Guru - Director of Investors RelationsConference Call ParticipantsDavid Westenberg - Managing Director and Equity Research AnalystDoug Shenko - Senior AnalystJack Meehan - Equity Research AnalystKyle Mixon - Equity Research AnalystMason Carrico - Equity Research AnalystSubbu Nambi - Managing Director and Healthcare ...

Pacific Biosciences of California (NasdaqGS:PACB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsChristian Henry - CEODan Brennan - Managing DirectorJim Gibson - CFOKelly Guru - Director of Investors RelationsConference Call ParticipantsDavid Westenberg - Managing Director and Equity Research AnalystDoug Shenko - Senior AnalystJack Meehan - Equity Research AnalystKyle Mixon - Equity Research AnalystMason Carrico - Equity Research AnalystSubbu Nambi - Managing Director and Healthcare ...

Pacific Biosciences of California (NasdaqGS:PACB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker9Good day, and welcome to PacBio's fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and t ...

Q4 & Full Year 2025 Earnings Presentation February 12, 2026 1 Safe harbor and non-GAAP disclosures Statement regarding use of non‐GAAP financial measures PacBio reports non‐GAAP results for basic net income and loss per share, net income, net loss, gross margins, gross profit and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information ...

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results: Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0<td colspan="1" style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: center ; vertical-align: middle; border-right: solid black 1pt ; border-left: solid black 1p ...

Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease NetworkMENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® long-read whole-genome sequencing into iHope’s international network. iHope operates the world’s largest ...

Core Viewpoint - PacBio has completed the sale of select intellectual property and assets related to its short-read DNA sequencing technology to Illumina, Inc., receiving $48.1 million in net cash proceeds from the transaction [1][2]. Group 1: Transaction Details - The transaction involved Illumina assuming certain liabilities and granting a non-exclusive license of specific intellectual property back to PacBio [2]. - The deal was finalized on January 30, 2026 [3]. Group 2: Strategic Focus - In response to challenging macroeconomic conditions, PacBio paused the development of its high-throughput short-read sequencing platform to concentrate on its long-read sequencing innovations [3]. - The sale strengthens PacBio's balance sheet and allows the company to focus on driving the adoption of its long-read sequencing platform, particularly the accelerated development of SPRQ-Nx chemistry [3]. Group 3: Company Overview - PacBio is a leading life science technology company that designs and manufactures advanced sequencing solutions for various research applications, including human germline sequencing, oncology, and infectious disease [4].